Portfolio company
Iris Medicine
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This life sciences company develops allele-selective ribonucleic acid therapies to treat genetic diseases in patients with repeat expansion disorders.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
3X Genetics
This company develops long-read genetic testing technology and diagnostics for biopharma companies to identify patients with rare repeat expansion disorders.
ARTHEx Biotech
This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.
Tacit Therapeutics
This company develops RNA trans-splicing medicines to repair genetic mutations for patients with inherited neurological diseases and other complex gene-mediated conditions.
Vico Therapeutics
This company develops antisense oligonucleotide therapies to treat patients with rare genetic neurological disorders, including Huntington's disease and spinocerebellar ataxias.
Aptadir Therapeutics
The company develops RNA inhibitor-based therapeutics that reactivate silenced genes to treat patients with intractable cancers and rare genetic conditions.